ESMO 2023 Lung Cancer – Gerrina Ruiter

Gerrina Ruiter explains the limitations of previous HER2 agents tested in solid tumors while highlighting the encouraging preliminary results of the BEAMION Lung-1 trial of zongertinib in HER2–mutant solid tumors. Lastly, she talks about the challenges of bispecific antibodies, which have recently shown robust efficacy in solid tumors.

Here is the full ESMO 2023 Lung Cancer report.